MLLT3 and intrahepatic cholangiocarcinoma: In contrast, discriminating KMT2A-r and MECOM-r cases from MLLT3- and GATA2- rearranged cases and accepting only specific partner genes according to ICC did not show differences regarding OS neither within rearranged cases nor compared to WHO 2022.